Leuprolide is a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.
CAT No: R1949
CAS No: 53714-56-0
Synonyms/Alias: Leuprorelin;leuprolide;53714-56-0;Leuproreline;Leuprorelinum;Leuporelin;Leuprorelina;(-)-leuprolide;UNII-EFY6W0M8TG;EFY6W0M8TG;TAP-144 FREE BASE;CCRIS 8462;CHEBI:6427;HSDB 6518;CKD-841;Leuprorelin slow release;ABBOTT-43818 FREE BASE;Leuproreline [INN-French];Leuprorelinum [INN-Latin];NSC 377526;NSC-377526;Leuprorelina [INN-Spanish];DTXSID50872411;(D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-GNRH;(D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-LHRH;Leuproreline (INN-French);Leuprorelinum (INN-Latin);Leuprorelina (INN-Spanish);LEUPRORELIN (MART.);LEUPRORELIN [MART.];5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide;pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHC2H5;Leuprorelin acetate (JAN);Leuprolide acetate (USAN);LEUPRORELIN (EP MONOGRAPH);LEUPRORELIN [EP MONOGRAPH];5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TRYOSYL-D-LEUCYL-L-LEUCYL-L-ARGINYL-N-ETHYL-L-PROLINAMIDE;L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide;LEUPRORELIN [INN];MFCD00167544;Leuprolide acetate salt;Leuprorelin [INN:BAN];Leuprorelin?;Leuprolide TFA;LEUPROLIDE [MI];LEUPROLIDE [HSDB];LEUPROLIDE [VANDF];SCHEMBL4585;LEUPRORELIN [WHO-DD];GTPL1175;CHEMBL1201199;DTXCID00820063;L02AE02;GFIJNRVAKGFPGQ-LIJARHBVSA-N;BDBM50369395;AKOS015892744;AKOS030213246;AKOS037515838;CCG-270656;CS-4947;DB00007;HS-2016;NCGC00485984-01;DA-64932;HY-12553;Leuprolide acetate salt, >=98% (HPLC);C75519;pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt;EN300-7481165;Fensolvi (leuprolide acetate injectable suspension);Q907160;BRD-K26323068-001-01-8;Leuprolide acetate, United States Pharmacopeia (USP) Reference Standard;6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig);(2S)-1-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2R)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-4-methylpentanamido]-4-methylpentanamido]pentanoyl]-N-ethylpyrrolidine-2-carboxamide;6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig);
Chemical Name: (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C59H84N16O12 |
M.W/Mr. | 1209.4 |
Sequence | One Letter Code:XHWSYLLRP Three Letter Code:H-Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt |
Appearance | Solid powder |
Activity | Agonist |
Biological Activity | Leuprolide is a peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty. |
Target | Gonadotropin-releasing hormone receptor |
Long-term Storage Conditions | Soluble in DMSO |
InChI | InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1 |
InChI Key | GFIJNRVAKGFPGQ-LIJARHBVSA-N |
Canonical SMILES | CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6 |
Isomeric SMILES | CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6 |
2. Myotropic activity of allatostatins in tenebrionid beetles
4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
5. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.